Mody C H, Toews G B, Lipscomb M F
Department of Internal Medicine, University of Michigan, Ann Arbor.
Am Rev Respir Dis. 1989 Jan;139(1):8-13. doi: 10.1164/ajrccm/139.1.8.
We previously demonstrated that prophylactic Cyclosporin-A (Cs-A) treatment of mice enhanced survival after inoculation of Cryptococcus neoformans by both the intratracheal (IT) and intravenous (IV) routes. In the present studies, we determined whether an established infection due to C. neoformans could be treated with Cs-A. Mice inoculated IT develop a prominent pulmonary infection with late dissemination to distant organs. The survival of mice infected by the pulmonary route that received Cs-A subcutaneously was prolonged in both immunologically intact and congenitally T-cell-deficient mice (athymic nude mice). In normal mice that received Cs-A, growth of C. neoformans was arrested in the lung, spleen, kidney, and liver, and the rapid rate of accumulation of organisms in the brain was slowed as compared to that of control mice. In nude mice, the organisms continued to increase in all organs although at a considerably slower rate than in untreated control nude mice. Mice given C. neoformans IV developed infection in the brain at the time of inoculation. When an inoculum was deposited in the brains of normal mice by giving the organism IV and Cs-A treatment initiated 3 days later, mice receiving Cs-A did not demonstrate a reduced number of C. neoformans in the brain as compared to untreated control mice. Thus, Cs-A was effective for treatment of extraneural cryptococcal infection in normal mice, but it was unable to reduce cryptococcal replication in the central nervous system.(ABSTRACT TRUNCATED AT 250 WORDS)
我们之前证明,对小鼠进行预防性环孢菌素A(Cs-A)治疗可提高经气管内(IT)和静脉内(IV)途径接种新型隐球菌后的存活率。在本研究中,我们确定了已建立的新型隐球菌感染是否可用Cs-A治疗。经IT接种的小鼠会发生明显的肺部感染,并在后期扩散至远处器官。皮下接受Cs-A治疗的经肺部途径感染的小鼠,在免疫功能正常和先天性T细胞缺陷小鼠(无胸腺裸鼠)中的存活率均延长。在接受Cs-A的正常小鼠中,新型隐球菌在肺、脾、肾和肝脏中的生长受到抑制,与对照小鼠相比,脑中病原体的快速积累速度减缓。在裸鼠中,病原体在所有器官中持续增加,尽管速度比未治疗的对照裸鼠慢得多。经IV接种新型隐球菌的小鼠在接种时脑部发生感染。当通过IV给正常小鼠脑部接种病原体并在3天后开始Cs-A治疗时,与未治疗的对照小鼠相比,接受Cs-A的小鼠脑中新型隐球菌的数量并未减少。因此,Cs-A对正常小鼠的神经外隐球菌感染有效,但无法减少中枢神经系统中的隐球菌复制。(摘要截短至250字)